vs
EXACT SCIENCES CORP（EXAS）与格罗方德（GFS）财务数据对比。点击上方公司名可切换其他公司
格罗方德的季度营收约是EXACT SCIENCES CORP的1.9倍（$1.7B vs $878.4M），格罗方德净利率更高（14.8% vs -9.8%，领先24.5%），EXACT SCIENCES CORP同比增速更快（23.1% vs -2.9%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -4.3%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
格罗方德是跨国半导体代工及设计企业，注册地为开曼群岛，总部位于美国纽约州马耳他。公司2009年3月由AMD制造业务分拆成立，2021年10月完成首次公开募股，阿联酋主权财富基金穆巴达拉投资公司目前仍持有其82%的多数股权。
EXAS vs GFS — 直观对比
营收规模更大
GFS
是对方的1.9倍
$878.4M
营收增速更快
EXAS
高出26.1%
-2.9%
净利率更高
GFS
高出24.5%
-9.8%
两年增速更快
EXAS
近两年复合增速
-4.3%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.7B |
| 净利润 | $-86.0M | $249.0M |
| 毛利率 | 70.1% | 24.8% |
| 营业利润率 | -9.4% | 11.6% |
| 净利率 | -9.8% | 14.8% |
| 营收同比 | 23.1% | -2.9% |
| 净利润同比 | 90.1% | 39.9% |
| 每股收益（稀释后） | $-0.45 | $0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASGFS
| Q4 25 | $878.4M | — | ||
| Q3 25 | $850.7M | $1.7B | ||
| Q2 25 | $811.1M | $1.7B | ||
| Q1 25 | $706.8M | $1.6B | ||
| Q4 24 | $713.4M | — | ||
| Q3 24 | $708.7M | $1.7B | ||
| Q2 24 | $699.3M | $1.6B | ||
| Q1 24 | $637.5M | $1.5B |
净利润EXASGFS
| Q4 25 | $-86.0M | — | ||
| Q3 25 | $-19.6M | $249.0M | ||
| Q2 25 | $-1.2M | $228.0M | ||
| Q1 25 | $-101.2M | $211.0M | ||
| Q4 24 | $-864.6M | — | ||
| Q3 24 | $-38.2M | $178.0M | ||
| Q2 24 | $-15.8M | $155.0M | ||
| Q1 24 | $-110.2M | $134.0M |
毛利率EXASGFS
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | 24.8% | ||
| Q2 25 | 69.3% | 24.2% | ||
| Q1 25 | 70.8% | 22.4% | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | 23.8% | ||
| Q2 24 | 69.8% | 24.2% | ||
| Q1 24 | 70.0% | 25.4% |
营业利润率EXASGFS
| Q4 25 | -9.4% | — | ||
| Q3 25 | -3.0% | 11.6% | ||
| Q2 25 | -0.3% | 11.6% | ||
| Q1 25 | -13.6% | 9.5% | ||
| Q4 24 | -122.8% | — | ||
| Q3 24 | -5.6% | 10.6% | ||
| Q2 24 | -3.8% | 9.5% | ||
| Q1 24 | -16.7% | 9.5% |
净利率EXASGFS
| Q4 25 | -9.8% | — | ||
| Q3 25 | -2.3% | 14.8% | ||
| Q2 25 | -0.1% | 13.5% | ||
| Q1 25 | -14.3% | 13.3% | ||
| Q4 24 | -121.2% | — | ||
| Q3 24 | -5.4% | 10.2% | ||
| Q2 24 | -2.3% | 9.5% | ||
| Q1 24 | -17.3% | 8.7% |
每股收益（稀释后）EXASGFS
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | $0.44 | ||
| Q2 25 | $-0.01 | $0.41 | ||
| Q1 25 | $-0.54 | $0.38 | ||
| Q4 24 | $-4.69 | — | ||
| Q3 24 | $-0.21 | $0.32 | ||
| Q2 24 | $-0.09 | $0.28 | ||
| Q1 24 | $-0.60 | $0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $2.0B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $11.8B |
| 总资产 | $5.9B | $16.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASGFS
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | $2.0B | ||
| Q2 25 | $858.4M | $1.8B | ||
| Q1 25 | $786.2M | $1.6B | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | $2.3B | ||
| Q2 24 | $946.8M | $2.2B | ||
| Q1 24 | $652.1M | $2.2B |
股东权益EXASGFS
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.5B | $11.8B | ||
| Q2 25 | $2.5B | $11.5B | ||
| Q1 25 | $2.4B | $11.1B | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $3.2B | $11.6B | ||
| Q2 24 | $3.2B | $11.3B | ||
| Q1 24 | $3.1B | $11.3B |
总资产EXASGFS
| Q4 25 | $5.9B | — | ||
| Q3 25 | $5.9B | $16.7B | ||
| Q2 25 | $5.8B | $16.8B | ||
| Q1 25 | $5.7B | $16.5B | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $6.7B | $18.1B | ||
| Q2 24 | $6.7B | — | ||
| Q1 24 | $6.4B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $595.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 2.39× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASGFS
| Q4 25 | $151.7M | — | ||
| Q3 25 | $219.9M | $595.0M | ||
| Q2 25 | $89.0M | $431.0M | ||
| Q1 25 | $30.8M | $331.0M | ||
| Q4 24 | $47.1M | — | ||
| Q3 24 | $138.7M | $375.0M | ||
| Q2 24 | $107.1M | $402.0M | ||
| Q1 24 | $-82.3M | $488.0M |
自由现金流EXASGFS
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASGFS
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASGFS
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASGFS
| Q4 25 | — | — | ||
| Q3 25 | — | 2.39× | ||
| Q2 25 | — | 1.89× | ||
| Q1 25 | — | 1.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.11× | ||
| Q2 24 | — | 2.59× | ||
| Q1 24 | — | 3.64× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
GFS
| Smart Mobile Devices | $752.0M | 45% |
| Automotive | $306.0M | 18% |
| Home And Industrial Io T | $258.0M | 15% |
| Goods Or Services Transferred Over Time | $198.0M | 12% |
| Communications Infrastructure Datacenter | $175.0M | 10% |
